|Tested species reactivity||Chicken|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant chicken Interferon beta|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Functional Assay (FN)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody does not cross-react with IFN gamma.
In Western blot, this antibody detects a band at ~20 kDa.
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by â€œNatural IFN-producing cells (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis. Reports suggest that chIFN exhibits properties similar to mammalian IFN type I (IFNI). Functional studies revealed the presence of two distantly related IFNI genes, designated as IFN alpha and IFN beta, found on chicken chromosome Z. The serological distinction between these two IFNs has been verified using neutralisation assays, and there is evidence that the antiviral activity of chIFN-beta is approximately ten-fold less compared to chIFN-alpha. This would suggest that chIFNbeta might have a different physiological role, though chIFN-beta is expressed strongly in virus-infected cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.